In this podcast, expert faculty, Dr Stuart Gordon and Dr Nancy Reau, use an illustrative patient case to explore the roles of ALP and other biochemical markers in PBC management, and explain what to expect from treatment. Topics covered include: 

• How baseline ALP can affect ALP normalization after second-line treatment with elafibranor and seladelpar
• Potential outcomes if ALP normalization cannot be achieved
• The importance of managing fatigue, pruritus, and sleep disturbances independently of the biochemical response

Presenters:

Stuart C. Gordon, MD
Professor of Medicine
Wayne State University School of Medicine
Director, Division of Hepatology
Henry Ford Health
Detroit, Michigan

Nancy Reau, MD
Professor of Medicine
Richard B. Capps Chair of Hepatology
Chief, Section of Hepatology
Associate Director, Solid Organ Transplantation
Rush University Medical Center
Chicago, Illinois

To learn more about PBC management, check out our program, 
Curbside Consults: Expert Insights on Challenges in PBC Management. 

Supported by educational grants from Gilead Sciences, Inc. and Ipsen Biopharmaceuticals, Inc